Friends/Family Support

A survivor shares tips on ways to practice gratitude the holiday season.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved relapse-free survival.

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA.